Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01468168
Recruitment Status : Completed
First Posted : November 9, 2011
Last Update Posted : December 17, 2012
Information provided by (Responsible Party):
Santen Inc.

Brief Summary:
To investigate the safety and efficacy of DE-101 to improve the signs and symptoms in dry-eye disease.

Condition or disease Intervention/treatment Phase
Dry Eye Disease Drug: DE-101 Ophthalmic Suspension Drug: DE-101 Ophthalmic Suspension Vehicle Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 183 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Study Start Date : October 2011
Actual Primary Completion Date : November 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Diseases

Arm Intervention/treatment
Experimental: DE-101 Ophthalmic Suspension High Dose Drug: DE-101 Ophthalmic Suspension
Ophthalmic suspension; QID

Experimental: DE-101 Ophthalmic Suspension Low Dose Drug: DE-101 Ophthalmic Suspension
Ophthalmic suspension; QID

Placebo Comparator: DE-101 Ophthalmic Suspension Vehicle Drug: DE-101 Ophthalmic Suspension Vehicle
Ophthalmic suspension vehicle; QID

Primary Outcome Measures :
  1. Tear volume increase from baseline [ Time Frame: baseline and 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Individuals considered for entry into the study will be of either sex and any race who have:
  • a confirmed diagnosis of dry eye,
  • are willing to use no ocular treatments during the study other than study medication,
  • have a corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity score of +0.7 logarithm of the minimum angle of resolution (logMAR) or better in each eye,
  • will not use contact lenses during the study,
  • Females of child-bearing potential must have a negative urine pregnancy test and be willing to use an acceptable method of contraception to be eligible for, and continue participation in, the study,
  • 18 years of age or older,
  • able to understand and provide written informed consent

Exclusion Criteria:

  • Subjects with any of the following are not eligible to participate in the study:
  • Fluorescein corneal staining or conjunctival staining that is too severe
  • Conditions requiring the use of ophthalmic prescription or over the counter medications during the study (except for study medications)
  • Any type of current punctal occlusion including punctal plugs, intracanalicular punctal plugs or cauterized puncta
  • Any type of ocular surgery within 90 days prior to Visit 1 (Day 1)
  • Known history of Steven-Johnson's syndrome, Riley-Day syndrome, and/or ocular pemphigoid
  • Ocular(including lid)disease/abnormality that may interfere with the study
  • Corneal transplant in either eye, at any time prior to enrollment in the study
  • Laser refractive surgery less than one year prior to Visit 1 (Day 1)
  • Conditions requiring the use of any systemic medication that is not ongoing at a stable dosage for at least 30 days prior to Visit 1 (Day 1)
  • Application of isotretinoin within 30 days prior to Visit 1 (Day 1)
  • Known allergy or sensitivity to any of the study medication components
  • Uncontrolled systemic conditions or other conditions which would confound the study evaluations or endanger the safety of the subject
  • A woman who is pregnant, nursing, or planning a pregnancy
  • Participation in another investigational drug or vaccine trial, or participation in such a trial within 30 days prior to Visit 1 (Day 1)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01468168

Layout table for location information
United States, California
New Port Beach, California, United States, 92663
United States, Colorado
Parker, Colorado, United States, 80134
United States, Florida
Largo, Florida, United States, 33773
United States, Georgia
Morrow, Georgia, United States, 30260
Roswell, Georgia, United States, 30076
United States, Maine
Bangor, Maine, United States, 04401
United States, Missouri
Kansas City, Missouri, United States, 64111
Saint Louis, Missouri, United States, 63131
Washington, Missouri, United States, 63090
United States, North Carolina
High Point, North Carolina, United States, 27262
United States, Ohio
Cleveland, Ohio, United States, 44115
United States, Utah
Salt Lake City, Utah, United States, 84107
United States, Virginia
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Santen Inc.

Layout table for additonal information
Responsible Party: Santen Inc. Identifier: NCT01468168    
Other Study ID Numbers: 26-005
First Posted: November 9, 2011    Key Record Dates
Last Update Posted: December 17, 2012
Last Verified: December 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Eye Diseases
Conjunctival Diseases
Corneal Diseases
Lacrimal Apparatus Diseases